---
title: Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells
  and residual disease in lung cancer
date: '2024-05-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38702301/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240504180808&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Targeted therapy is effective in many tumor types including lung cancer,
  the leading cause of cancer mortality. Paradigm defining examples are targeted therapies
  directed against non-small cell lung cancer (NSCLC) subtypes with oncogenic alterations
  in EGFR, ALK and KRAS. The success of targeted therapy is limited by drug-tolerant
  persister cells (DTPs) which withstand and adapt to treatment and comprise the residual
  disease state that is typical during treatment with clinical ...
disable_comments: true
---
Targeted therapy is effective in many tumor types including lung cancer, the leading cause of cancer mortality. Paradigm defining examples are targeted therapies directed against non-small cell lung cancer (NSCLC) subtypes with oncogenic alterations in EGFR, ALK and KRAS. The success of targeted therapy is limited by drug-tolerant persister cells (DTPs) which withstand and adapt to treatment and comprise the residual disease state that is typical during treatment with clinical ...